Tigecycline and the need for a new broad-spectrum antibiotic class

Surgical Infections

Volumn 7, Issue 1, 2006, Pages 69-80

  Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; METICILLIN; MINOCYCLINE; NEW DRUG; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PENICILLIN RESISTANCE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MINOCYCLINE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33645572048     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.7.69     Document Type: Review

References (83)

1. Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004;38:1279-1286.
2. Overbye KM, Barrett JF. Antibiotics: Where did we go wrong? Drug Discov Today 2005;10:45-52.
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in U.S. hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39: 309-317.
4. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-1435.
5. European Society for Clinical Microbiology and Infectious Diseases. European Antimicrobial Resistance Surveillance System Annual Report. 2002.
6. Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004;10:1627-1634.
7. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36: 53-59.
8. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-598.
9. Melzer M, Eykyn SJ, Gransden WR, et al. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003;37: 1453-1460.
10. Paladino JA, Sunderlin JL, Price CS, et al. Economic consequences of antimicrobial resistance. Surg Infect 2002;3:259-267.
11. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-1132.
12. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: Emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35: 819-824.
13. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598.
14. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797-800.
15. Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-1058.
16. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Chn Infect Dis 2005;40:100-107.
17. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired metwcilhn-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003;9:978-984.
18. Diep BA, Sensabaugh GF, Somboona NS, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004;42:2080-2084.
19. Liassine N, Auckenthaler R, Descombes MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004;42:825-828.
20. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002;51:565-567.
21. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721.
22. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135:175-183.
23. Lautenbach E, LaRosa LA, Marr AM, et al. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: Impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003;36:440-446.
24. Rapp RP. Emerging bacterial pathogens: A consensus of the scientific data and the risk for development of multiple organ dysfunction syndrome. Surg Infect 2000;1:187-196.
25. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145-158.
26. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: A prospective multicenter study. Ann Intern Med 2001;135:484-492.
27. Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001;33:445-452.
28. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-2228.
29. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect Control Hosp Epidemiol 2003;24:690-698.
30. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment. J Infect Dis 2000;182:1417-1424.
31. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34:1613-1620.
32. Jacobs MR. Streptococcus pneumoniae: Epidemiology and patterns of resistance. Am J Med 2004;117(suppl 3A):3S-15S.
33. European Society for Clinical Microbiology and Infectious Diseases. European Antimicrobial Resistance Surveillance System Annual Report. 2003.
34. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
35. Kim BN, Woo JH, Kim MN, et al. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002;52:99-106.
36. Arpin C, Dubois V, Coulange L, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47:3506-3514.
37. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39:55-60.
38. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32.
39. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-1094.
40. Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004;54:735-743.
41. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intensive Care Med 2002;28: 1718-1723.
42. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-37.
43. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumanni aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med 2002;162:1515-1520.
44. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:1268-1274.
45. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-569.
46. Zarrilli R, Crispino M, Bagattini M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004;42:946-953.
47. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: Are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003;36:1006-1012.
48. Wilcox MH. Antibiotic prescribing as a risk factor for MRSA. Medicine 2005;66:180-184.
49. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-1422.
50. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002;49:999-1005.
51. Muller AA, Mauny F, Bertin M, et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003;36:971-978.
52. Crowcroft NS, Ronveaux O, Monnet DL, et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999;20:31-36.
53. Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004;10:1432-1441.
54. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004;64:63-88.
55. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001;40:173-177.
56. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-895.
57. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrobial Agents Chemother 2002;46:3164-3167.
58. Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 2004;24:567-571.
59. Reynolds R, Potz N, Colman M, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004;53:1018-1032.
60. Stevens TB, Johnson JJ, Bouchillon S, et al. Tigecycline Evaluation Surveillance Trial (T.E.S.T.): In vitro antibacterial activity against selected species of Enterobacteriaceae [abstract E-2063]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
61. Huang V, Rybak MJ. Evaluation of tigecycline (TG), minocycline (MN), tetracycline (TT), teicoplanin (TP), and vancomycin (VN) against community-associated (CA-MRSA) and multidrug-resistant (MDR-MRSA) methicillin-resistant Staphylococcus aureus [abstract E-2063]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
62. Fritsche TR, Strabala P, Sader HS, et al. Activity of tigecycline (TIG) tested against tetracycline-resistant Enterobacteriaceae [abstract E-2058]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
63. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48: 4479-4481.
64. Mercier R-C, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517-1523.
65. Petersen PJ, Weiss WJ, Labthavikul P, et al. The postantibiotic effect and time-kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO) and (PAM-MINO) [abstract F-132]. In 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38:24.
66. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-949.
67. Kucers A, Bennet NM (eds). Tetracyclines. In The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. London: William Heinemann Medical Books, 1979:592-645.
68. Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-599.
69. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994;38:1658-1660.
70. Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharmaceut Design 1998;4:119-132.
71. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-2228.
72. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44:2225-2229.
73. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20:219S-223S.
74. Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47:665-669.
75. Visalli MA, Projan SJ, Bradford PA. Multidrug-resistant gene (MDR), rama, is associated with decreased susceptibility to tigecycline (TGC) in Klebsiella pneumoniae (Kp) [abstract C1-1600]. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002.
76. Ruzin A, Keeney D, Visalli MA, et al. AcrAB efflux-mediated decreased susceptibility to tigecycline in Enterobacter spp. [abstract C1-1198]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
77. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-229.
78. Owen JS, Darling IM, Troy SM, et al. Noncompartmental pharmacokinetics of tigecycline in patients with complicated skin and skin structure infections [abstract A-11]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
79. Tombs NL. Tissue distribution of Gar-936, a broadspectrum antibiotic, in male rats [abstract 413]. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999.
80. Postier RG, Green SL, Klein SR, et al. A multicenter, randomized, open-label safety and efficacy study of tigecycline dosages for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004;26:704-714.
81. Murray J, Wilson S, Klein S, et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients: A phase 2 clinical trial [abstract L-739]. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003.
82. Dartois N on behalf of the Tigecycline for Complicated Skin and Skin Structure Infections Group. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infecfions [abstract L-986]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.
83. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, et al. Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal infections [abstract L-992c]. In 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 30-November 2, 2004.